GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
NCT05660967 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE2
Lead sponsorGenmab
Last update2026-10-23
Public-record facts
| Intervention | Epcoritamab (BIOLOGICAL), Lenalidomide (DRUG) |
|---|---|
| Condition | Diffuse Large B-Cell Lymphoma |
| Enrollment | 111 |
| Why stopped | The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected safety findings were identified, and the decision to terminate was not related to participant safety. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-23.
- It is an interventional PHASE2 study with a named biological/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT05660967. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.